Oppenheimer Initiates Coverage on Rani Therapeutics (NASDAQ:RANI)

Oppenheimer started coverage on shares of Rani Therapeutics (NASDAQ:RANI – Free Report) in a research report released on Friday morning, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $17.00 target price on the stock. A number of other brokerages have also recently commented on RANI. BTIG Research boosted their target price on […]

Leave a Reply

Your email address will not be published.

Previous post Sight Sciences (NASDAQ:SGHT) Given “Hold” Rating at Needham & Company LLC
Next post Regeneron Pharmaceuticals (NASDAQ:REGN) PT Raised to $1,200.00